Company Statements

March 23, 2023

Kite’s Yescarta® First CAR T-cell Therapy to Receive Health Canada Authorization for Use as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

February 17, 2023

Christi Shaw to Depart Gilead and Kite Leadership End of Q1

January 26, 2023

Kite’s Yescarta® is First CAR T-cell Therapy Recommended for Routine Use in England, United Kingdom

January 10, 2023

Kite Expands Cell Therapy Manufacturing Operations in Maryland

November 7, 2022

Supreme Court Denied Juno’s Appeal Request in Juno vs. Kite Case

September 30, 2022

Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia

August 31, 2022

Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia

August 19, 2021

Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma

August 5, 2021

Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma

February 9, 2021

Kite Announces U.S. FDA Clearance of Investigational New Drug Application for KITE-222, an Anti-CLL-1 CAR T-Cell Therapy Candidate for Acute Myeloid Leukemia